GeneCentric Therapeutics, Inc., a Research Triangle Park, N.C.-based RNA-based genomic solutions provider, acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.
The amount of the deal was not disclosed.
The acquisition provides the combined company with a comprehensive, integrated set of RNA-based solutions to enhance drug development by identifying the right patients for oncology drugs, improving response rates and durability, and ultimately patient outcomes.
Led by Dr. Michael Milburn, CEO & President, and Dr. Myla Lai-Goldman, founder and Executive Chair, GeneCentric provides technologies designed to parse the complexity of tumor biology and generate signatures to responder populations to oncology drugs. The company is commercializing its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout pre-clinical testing, clinical drug development and commercialization lifecycle phases.
Founded by two University of North Carolina researchers, Benjamin Vincent, MD, an expert in computational immune-genomics, and Joel Parker, PhD, a genomics and data science expert, Select ImmunoGenomics supported clients at research as well as at diagnostics and drug development organizations. Drs. Vincent and Parker will serve as advisors to GeneCentric.